Systematic functional characterization of resistance to PI3K inhibition in breast cancer

Cancer Discovery

Volumn 6, Issue 10, 2016, Pages 1134-1147

  Le, Xiuning ^a,b,c   Antony, Rajee ^a,b   Razavi, Pedram ^d   Treacy, Daniel J ^a,b   Luo, Flora ^a,b   Ghandi, Mahmoud ^a,b   Castel, Pau ^d   Scaltriti, Maurizio ^d   Baselga, José ^d   Garraway, Levi A ^a,b,e  

^a DANA FARBER CANCER INSTITUTE   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; GUANINE NUCLEOTIDE EXCHANGE FACTOR; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; NVP-BYL719; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CA PROTEIN, HUMAN; PIM1 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; PROTEIN KINASE PIM 1; THIAZOLE DERIVATIVE;

ARTICLE; BREAST CANCER; CELL VIABILITY; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; OPEN READING FRAME; PHENOTYPE; PREVALENCE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR BIOPSY; UPREGULATION; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG RESISTANCE; FEMALE; GENE EXPRESSION REGULATION; GENETICS; MCF-7 CELL LINE; TUMOR CELL LINE;

BREAST NEOPLASMS; CELL LINE, TUMOR; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MCF-7 CELLS; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-PIM-1; THIAZOLES; UP-REGULATION;

EID: 84994131487     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-16-0305     Document Type: Article

References (50)

1. Wong K-K, Engelman JA, Cantley LC. Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev 2010; 20: 87–90.
2. Baselga J. Targeting the phosphoinositide-3 (PI3) kinase pathway in breast cancer. Oncologist. 2011; 16: 12–9.
3. Cantley LC. The phosphoinositide 3-kinase pathway. Science 2002; 296: 1655–7.
4. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004; 304: 554.
5. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase–AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489–501.
6. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61–70.
7. Fritsch C, Huang A, Chatenay-Rivauday C, Schnell C, Reddy A, Liu M, et al. Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials. Mol Cancer Ther 2014; 13: 1117–29.
8. Juric D, Rodon J, Gonzalez-Angulo A, Baselga J. Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72:Abstract nr CT-01.
9. Vora SR, Juric D, Kim N, Mino-Kenudson M, Huynh T, Costa C, et al. CDK 4/6 inhibitors sensitize PIK3CA mutant breast cancer to PI3K inhibitors. Cancer Cell 2014; 26: 136–49.
10. Ilic N, Utermark T, Widlund HR, Roberts TM. PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A 2011; 108: E699–708.
11. Bosch A, Li Z, Bergamaschi A, Ellis H, Toska E, Prat A, et al. PI3K inhibition results in enhanced estrogen receptor function and dependence in hormone receptor-positive breast cancer. Sci Transl Med 2015; 7: 283ra51.
12. Juric D, Castel P, Griffith M, Griffith OL, Won HH, Ellis H, et al. Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor. Nature 2015; 518: 240–4.
13. Costa C, Ebi H, Martini M, Beausoleil SA, Faber AC, Jakubik CT, et al. Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer. Cancer Cell 2015; 27: 97–108.
14. Elkabets M, Vora S, Juric D, Morse N, Mino-Kenudson M, Muranen T, et al. mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancer. Sci Transl Med 2013; 5: 196ra99.
15. Kohn AD, Summers SA, Birnbaum MJ, Roth RA. Expression of a constitutively active Akt Ser/Thr Kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation. J Biol Chem 1996; 271: 31372–8.
16. Johannessen CM, Johnson LA, Piccioni F, Townes A, Frederick DT, Donahue MK, et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition. Nature 2013; 504: 138–42.
17. Wilson FH, Johannessen CM, Piccioni F, Tamayo P, Kim JW, Van Allen EM, et al. A functional landscape of resistance to ALK inhibition in lung cancer. Cancer Cell 2015; 27: 397–408.
18. Keramati AR, Fathzadeh M, Go G-W, Singh R, Choi M, Faramarzi S, et al. A form of the metabolic syndrome associated with mutations in DYRK1B. N Engl J Med 2014; 370: 1909–19.
19. Goumidi L, Cottel D, Dallongeville J, Amouyel P, Meirhaeghe A. Effects of established BMI-associated loci on obesity-related traits in a French representative population sample. BMC Genet. 2014; 15: 62.
20. Kitamoto A, Kitamoto T, Mizusawa S, Teranishi H, So R, Matsuo T, et al. NUDT3 rs206936 is associated with body mass index in obese Japanese women. Endocr J. 2013; 60: 991–1000.
21. James FR, Wootton S, Jackson A, Wiseman M, Copson ER, Cutress RI. Obesity in breast cancer–what is the risk factor? Eur J Cancer Oxf Engl 1990 2015; 51: 705–20.
22. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov 2012; 2: 401–4
23. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 2011; 12: R41.
24. Narlik-Grassow M, Blanco-Aparicio C, Carnero A. The PIM family of serine/threonine kinases in cancer. Med Res Rev 2014; 34: 136–59.
25. Burger MT, Nishiguchi G, Han W, Lan J, Simmons R, Atallah G, et al. Identification of N-(4-((1R,3S,5S)-3-Amino-5-methylcyclohexyl) pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (PIM447), a potent and selective proviral insertion site of moloney murine leukemia (PIM) 1, 2, and 3 kinase inhibitor in clinical trials for hematological malignancies. J Med Chem 2015; 58: 8373–86.
26. Warfel NA, Kraft AS. PIM kinase (and Akt) biology and signaling in tumors. Pharmacol Ther 2015; 151: 41–9.
27. Weigelt B, Warne PH, Downward J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 2011; 30: 3222–33.
28. Emery CM, Vijayendran KG, Zipser MC, Sawyer AM, Niu L, Kim JJ, et al. MEK1 mutations confer resistance to MEK and B-RAF inhibition. Proc Natl Acad Sci U S A 2009; 106: 20411–6.
29. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039–43.
30. Peng C, Knebel A, Morrice NA, Li X, Barringer K, Li J, et al. Pim kinase substrate identification and specificity. J Biochem (Tokyo) 2007; 141: 353–62.
31. Zhang Y, Wang Z, Magnuson NS. Pim-1 kinase-dependent phosphorylation of p21Cip1/WAF1 regulates its stability and cellular localization in H1299 cells. Mol Cancer Res MCR 2007; 5: 909–22.
32. Aho TLT, Sandholm J, Peltola KJ, Mankonen HP, Lilly M, Koskinen PJ. Pim-1 kinase promotes inactivation of the pro-apoptotic Bad protein by phosphorylating it on the Ser112 gatekeeper site. FEBS Lett 2004; 571: 43–9.
33. Wang Z, Bhattacharya N, Mixter PF, Wei W, Sedivy J, Magnuson NS. Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 2002; 1593: 45–55.
34. Morishita D, Katayama R, Sekimizu K, Tsuruo T, Fujita N. Pim kinases promote cell cycle progression by phosphorylating and downregulating p27Kip1 at the transcriptional and posttranscriptional levels. Cancer Res 2008; 68: 5076–85.
35. Keeton EK, McEachern K, Dillman KS, Palakurthi S, Cao Y, Grondine MR, et al. AZD1208, a potent and selective pan-Pim kinase inhibitor, demonstrates efficacy in preclinical models of acute myeloid leukemia. Blood 2014; 123: 905–13.
36. Garcia P, Langowski J, Holash J, Burger M, Zang R, Zavorotinskaya T, et al. The pan-PIM kinase inhibitor LGH447 shows activity in PIM2- dependent multiple myeloma and in AML models. ASH 2013; 122: 1666
37. Cen B, Mahajan S, Wang W, Kraft AS. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res 2013; 73: 3402–11.
38. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012; 483: 603–7.
39. Elkabets M, Pazarentzos E, Juric D, Sheng Q, Pelossof RA, Brook S, et al. AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas. Cancer Cell 2015; 27: 533–46.
40. Wheeler DL, Iida M, Dunn EF. The role of Src in solid tumors. The Oncologist 2009; 14: 667–78.
41. Chen R, Kim O, Yang J, Sato K, Eisenmann KM, McCarthy J, et al. Regulation of Akt/PKB activation by tyrosine phosphorylation. J Biol Chem 2001; 276: 31858–62.
42. Meja K, Stengel C, Sellar R, Huszar D, Davies BR, Gale RE, et al. PIM and AKT kinase inhibitors show synergistic cytotoxicity in acute myeloid leukaemia that is associated with convergence on mTOR and MCL1 pathways. Br J Haematol 2014; 167: 69–79.
43. Walpen T, Kalus I, Schwaller J, Peier MA, Battegay EJ, Humar R. Nuclear PIM1 confers resistance to rapamycin-impaired endothelial proliferation. Biochem Biophys Res Commun 2012; 429: 24–30.
44. Hammerman PS, Fox CJ, Birnbaum MJ, Thompson CB. Pim and Akt oncogenes are independent regulators of hematopoietic cell growth and survival. Blood 2005; 105: 4477–83.
45. Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 2010; 468: 968–72.
46. Yip-Schneider MT, Horie M, Broxmeyer HE. Transcriptional induction of pim-1 protein kinase gene expression by interferon gamma and posttranscriptional effects on costimulation with steel factor. Blood 1995; 85: 3494–502.
47. Malinen M, Jääskeläinen T, Pelkonen M, Heikkinen S, Väisänen S, Kosma V-M, et al. Proto-oncogene PIM-1 is a novel estrogen receptor target associating with high grade breast tumors. Mol Cell Endocrinol 2013; 365: 270–6.
48. Vasudevan KM, Barbie DA, Davies MA, Rabinovsky R, McNear CJ, Kim JJ, et al. AKT-Independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell 2009; 16: 21–32.
49. Wang Y, Zhou D, Phung S, Masri S, Smith D, Chen S. SGK3 is an estrogen-inducible kinase promoting estrogen-mediated survival of breast cancer cells. Mol Endocrinol Baltim Md 2011; 25: 72–82.
50. Moody SE, Schinzel AC, Singh S, Izzo F, Strickland MR, Luo L, et al. PRKACA mediates resistance to HER2-targeted therapy in breast cancer cells and restores anti-apoptotic signaling. Oncogene 2015; 34: 2061–71.